Providers/Grant Support
This activity is jointly provided by Global Education Group and Iridium Continuing Education, in collaboration with The University of Colorado Division of Hematology.
This educational activity is supported by an educational grant from Johnson & Johnson.
Credits Available
- Physicians — maximum of 0.75 AMA PRA Category 1 Credit™
- Nurses — 0.75 Nursing Contact Hour
All other healthcare professionals completing this course will be issued a statement of participation
Target Audience
This activity is designed to meet the educational needs of hematologists/oncologists in both the academic and community setting as well as advanced practice providers and other HCPs involved in the management of patients with RRMM.
Program Overview
Advances in bispecific antibodies (BsAbs) and CAR T-cell therapy have transformed the treatment landscape for relapsed/refractory multiple myeloma (RRMM). However, with rapid developments come significant challenges: integrating novel agents into patient-specific care plans, sequencing therapies appropriately, and managing unique toxicities such as cytokine release syndrome (CRS) and ICANS. Variability in protocols and transitions between academic and community oncology settings further contribute to fragmented care.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Differentiate between BCMA and GPRC5D-targeting BsAbs based on specific mechanisms of action, efficacy data, and safety profiles to select optimal agents for individual patients with RRMM.
- Construct patient-specific treatment sequences incorporating BsAbs into existing treatment plans based on prior treatments, disease characteristics, and comorbidities.
- Implement evidence-based strategies for mitigating and managing CRS and neurological toxicities associated with BsAbs in both inpatient and outpatient settings, including step-up dosing protocols, specific monitoring parameters, and thresholds for intervention.
- Formulate a structured communication plan between academic and community practitioners to ensure safe transitions of care for patients receiving BsAbs.
Faculty
Joseph Mikhael, MD, Med, FRCPC, FACP, FASCO
Professor, Translational Genomics Research Institute
City of Hope Cancer Center
Chief Medical Officer
International Myeloma Foundation
Phoenix, Arizona
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Iridium CE. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring for a maximum of .75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
Global Education Group is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
This educational activity for 0.75 contact hours including 0.0 pharmacotherapeutic contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Relevant Financial Relationships
Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
Disclosures of Conflicts of Interest
Joseph Mikhael, MD, Med, FRCPC, FACP, FASCO
- Consulting Fee (e.g, Advisory Board): BMS, Janssen, Menarini, Sanofi
Instructions For Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be available for the participant to download.
Course Viewing Requirements
Supported Browsers:
Desktop: Newest and last prior version of Google Chrome, Firefox, Safari, and Microsoft Edge
Mobile devices: Newest and last prior version of Safari and Google Chrome
Supported Phones & Tablets:
All devices
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Iridium CE do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or [email protected].
